New research to be presented at the European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) shows that patients using GLP-1 or combined GLP-1 / GIP receptor agonist therapy for weight loss experienced minimal lean muscle mass loss as they lost weight across six months of treatment.
This article was originally published on MedicalXpress.com